Soliris is a formulation of Eculizumab, a humanized monoclonal antibody. This medicine is used in the treatment of patients diagnosed with myasthenia gravis. This disease is a long-term neuromuscular condition. Eculizumab is also used in the prevention of red blood cell breakdown. It is indicated to patients weighing above 5 kilograms (11 pounds) to treat various blood disorders. Soliris (Eculizumab) is available in the strength of 300mg as injections for intravenous (IV) use only.
Pharmacodynamics
Soliris comprises Eculizumab as its active salt. It is a monoclonal antibody that inhibits the cleavage of complement protein C5 into C5a and C5b, as well as the development of the terminal complement complex C5b-9. Complement-mediated intravascular hemolysis in paroxysmal nocturnal hemoglobinuria, complement-mediated microangiopathy in atypical hemolytic uremic syndrome, and immune-mediated inflammation and central nervous system damage in neuromyelitis optica spectrum disorder are all prevented by inhibiting this complex.
Interactions
The following are some interactions of Soliris (Eculizumab) injection with other drugs and diseases. You may require dose modifications.
With Medicines
- Immune globulin
- Efgartigimod alfa
With Diseases
- Meningococcal infections
- Infections
- Progressive multifocal leukoencephalopathy
- Thrombotic microangiopathy
With Alcohol
Soliris (Eculizumab) injection may interact with alcoholic drinks. This may lead to severe effects. Thus, it’s advisable to avoid alcohol consumption.
Contraindications
Soliris (Eculizumab) injection is not indicated for use in the following conditions.
- Hypersensitivity
- Allergy to Eculizumab
- Pregnancy
- Breastfeeding


